{"drugs":["Bacillus of Calmette and Guerin Vaccine, Live","BCG Vaccine","Theracys","Tice BCG"],"mono":{"0":{"id":"922388-s-0","title":"Generic Names","mono":"Bacillus of Calmette and Guerin Vaccine, Live"},"1":{"id":"922388-s-1","title":"Dosing and Indications","sub":{"0":{"id":"922388-s-1-4","title":"Adult Dosing","mono":"<ul><li>there are no data to support interchangeability of BCG live products<\/li><li><b>Carcinoma in situ of bladder; Treatment and Prophylaxis:<\/b> TheraCys(R) BCG Live (Connaught strain): induction therapy, 1 vial (81 mg) INTRAVESICALLY once weekly for 6 weeks, beginning a minimum of 14 days following transurethral resection; maintenance therapy, 1 vial (81 mg) INTRAVESICALLY at 3, 6, 12, 18, and 24 months following initial dose<\/li><li><b>Carcinoma in situ of bladder; Treatment and Prophylaxis:<\/b> TICE(R) BCG Live (TICE(R) strain): induction therapy, 1 vial (50 mg) INTRAVESICALLY once weekly for 6 weeks beginning 7 to 14 days following bladder biopsy, may repeat induction schedule once if tumor remission not achieved, and if clinical circumstances warrant; maintenance therapy, 1 vial (50 mg) INTRAVESICALLY once monthly for 6 to 12 months<\/li><li><b>Malignant tumor of urinary bladder, Stage Ta and\/or T1 papillary tumors following transurethral resection; Prophylaxis:<\/b> TheraCys(R) BCG Live (Connaught strain): induction therapy, 1 vial (81 mg) INTRAVESICALLY once weekly for 6 weeks, beginning a minimum of 14 days following transurethral resection; maintenance therapy, 1 vial (81 mg) INTRAVESICALLY at 3, 6, 12, 18, and 24 months following initial dose<\/li><li><b>Malignant tumor of urinary bladder, Stage Ta and\/or T1 papillary tumors following transurethral resection; Prophylaxis:<\/b> TICE(R) BCG Live (TICE(R) strain): induction therapy, 1 vial (50 mg) INTRAVESICALLY once weekly for 6 weeks beginning 7 to 14 days following bladder biopsy, may repeat induction schedule once if tumor remission not achieved, and if clinical circumstances warrant; maintenance therapy, 1 vial (50 mg) INTRAVESICALLY once monthly for 6 to 12 months<\/li><li><b>Tuberculosis; Prophylaxis:<\/b> 0.2 to 0.3 mL PERCUTANEOUSLY x 1<\/li><\/ul>"},"1":{"id":"922388-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Tuberculosis; Prophylaxis:<\/b> 1 month of age and older, 0.2 to 0.3 mL PERCUTANEOUSLY x 1<\/li><li><b>Tuberculosis; Prophylaxis:<\/b> younger than 1 month, one-half of adult dose (by reconstituting vial with 2 mL of sterile water)<\/li><\/ul>"},"3":{"id":"922388-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Carcinoma in situ of bladder; Treatment and Prophylaxis<\/li><li>Malignant tumor of urinary bladder, Stage Ta and\/or T1 papillary tumors following transurethral resection; Prophylaxis<\/li><li>Tuberculosis; Prophylaxis<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Breast cancer<\/li><li>Carcinoma of prostate<\/li><li>Colon cancer<\/li><li>Malignant lymphoma<\/li><li>Malignant melanoma<\/li><\/ul>"}}},"2":{"id":"922388-s-2","title":"Black Box Warning","mono":"<b>Intravesical (Powder for Suspension)<\/b><br\/>Bacillus of Calmette and Gu rin (BCG) infections have been reported in health care workers and in patients because of exposure to the vaccine during preparation and administration. Serious and fatal disseminated BCG infections have occurred and the risk is increased with intravesical administration. THERACYS(R) and TICE(R) BCG contain live attenuated mycobacteria and because of the potential risk for transmission, it should be prepared, handled, and disposed of as a biohazard material.<br\/>"},"3":{"id":"922388-s-3","title":"Contraindications\/Warnings","sub":[{"id":"922388-s-3-9","title":"Contraindications","mono":"<ul><li>at risk for BCG infection, including concurrent febrile illness, UTI, or macroscopic hematuria; postpone treatment until resolution<\/li><li>BCG systemic reaction, current or history; a minimum of 7  to 14 days must elapse before administration of BCG after biopsy, transurethral resection, or traumatic catheterization<\/li><li>hypersensitivity to BCG or any component of the product or hypersensitivity demonstrated with other medicinal agents that contain the same ingredients (TheraCys(R))<\/li><li>immunosuppressed persons, including HIV infection, or congenital or acquired immune deficiencies, including concomitant disease, cancer therapy, or immunosuppressive therapy; increased risk for disseminated BCG infection<\/li><li>tuberculosis, active<\/li><\/ul>"},{"id":"922388-s-3-10","title":"Precautions","mono":"<ul><li>BCG infections have been reported in health care workers; exposure primarily by accidental needle sticks or exposure to broken skin during preparation\/administration; use aseptic techniques, avoid needle stick injuries and exposure to broken skin<\/li><li>drug contains live attenuated mycobacteria; prepare, handle, and dispose as biohazardous material<\/li><li>disseminated infections, serious or fatal have been reported; increased risk when administered intravesically<\/li><li>nosocomial infections have been reported in patients who received parenteral drugs prepared in areas where BCG was prepared<\/li><li>arterial aneurysm, preexisting; increased risk of BCG infection; weigh benefit-to-risk before use (TheraCys(R))<\/li><li>bacterial UTI developing during treatment; withhold treatment until complete resolution of UTI (TheraCys(R))<\/li><li>concomitant use with prophylactic antimycobacterial drugs should be avoided (TheraCys(R))<\/li><li>latex allergy; vial stopper contains natural rubber latex (TheraCys(R))<\/li><li>men with BCG genitourinary tract infection (eg, orchitis\/epididymitis); infections have been refractory to antituberculous therapy and orchiectomy was required; monitoring recommended<\/li><li>prosthetic device of any kind; increased risk of infection; weigh benefit-to-risk before use<\/li><li>small bladder capacity; increased risk of bladder contracture  or severe local reactions<\/li><li>systemic BCG reaction\/infection, some fatal, have been reported; increased risk if administered within 2 weeks of either biopsy, transurethral resection, or traumatic catheterization; avoid trauma or introduction of contaminants to the urinary tract; wait at least 14 days after traumatic catheterization before treatment; monitoring recommended; permanently discontinue if suspected and promptly initiate treatment with 2 or more antimycobacterial agents; negative cultures do not rule out infection; BCG infection is not sensitive to pyrazinamide<\/li><li>voided urine within 6 hours after treatment should be treated as infectious waste; disinfect voided urine for 15 minutes with household bleach in the toilet before flushing; caregivers, family, close contacts should avoid contact with voided urine<\/li><li>report suspected adverse reactions to US Food and Drug Administration at 1-800-332-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"922388-s-3-11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>B2 (AUS)<\/li><\/ul>"},{"id":"922388-s-3-12","title":"Breast Feeding","mono":"<ul><li>WHO: Compatible with breastfeeding.<\/li><li>Micromedex: Infant risk is minimal.<\/li><\/ul>"}]},"4":{"id":"922388-s-4","title":"Drug Interactions","sub":{"1":{"id":"922388-s-4-14","title":"Major","mono":"<ul><li>Aclarubicin (established)<\/li><li>Adalimumab (theoretical)<\/li><li>Aldesleukin (established)<\/li><li>Altretamine (established)<\/li><li>Amonafide (established)<\/li><li>Amsacrine (established)<\/li><li>Asparaginase (established)<\/li><li>Azacitidine (established)<\/li><li>Azathioprine (established)<\/li><li>Bleomycin (established)<\/li><li>Broxuridine (established)<\/li><li>Busulfan (established)<\/li><li>Capecitabine (established)<\/li><li>Carboplatin (established)<\/li><li>Carmustine (established)<\/li><li>Certolizumab Pegol (theoretical)<\/li><li>Chlorambucil (established)<\/li><li>Cisplatin (established)<\/li><li>Cladribine (established)<\/li><li>Cyclophosphamide (established)<\/li><li>Cyclosporine (theoretical)<\/li><li>Cytarabine (established)<\/li><li>Cytarabine Liposome (established)<\/li><li>Dacarbazine (established)<\/li><li>Dactinomycin (established)<\/li><li>Daunorubicin (established)<\/li><li>Daunorubicin Citrate Liposome (established)<\/li><li>Decitabine (established)<\/li><li>Docetaxel (established)<\/li><li>Doxifluridine (established)<\/li><li>Doxorubicin (established)<\/li><li>Doxorubicin Hydrochloride Liposome (established)<\/li><li>Edatrexate (established)<\/li><li>Eflornithine (established)<\/li><li>Epirubicin (established)<\/li><li>Estramustine (established)<\/li><li>Etanercept (established)<\/li><li>Etoposide (established)<\/li><li>Everolimus (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Floxuridine (established)<\/li><li>Fludarabine (established)<\/li><li>Fluorouracil (established)<\/li><li>Fotemustine (established)<\/li><li>Gallium Nitrate (established)<\/li><li>Gemcitabine (established)<\/li><li>Golimumab (theoretical)<\/li><li>Hydroxyurea (established)<\/li><li>Idarubicin (established)<\/li><li>Ifosfamide (established)<\/li><li>Immune Globulin (probable)<\/li><li>Infliximab (theoretical)<\/li><li>Irinotecan (established)<\/li><li>Lomustine (established)<\/li><li>Mechlorethamine (established)<\/li><li>Melphalan (established)<\/li><li>Mercaptopurine (established)<\/li><li>Methotrexate (established)<\/li><li>Mitolactol (established)<\/li><li>Mitomycin (established)<\/li><li>Mitotane (established)<\/li><li>Mitoxantrone (established)<\/li><li>Mycophenolic Acid (theoretical)<\/li><li>Oxaliplatin (established)<\/li><li>Paclitaxel (established)<\/li><li>Pegaspargase (established)<\/li><li>Pentostatin (established)<\/li><li>Pipobroman (established)<\/li><li>Pirarubicin (established)<\/li><li>Plicamycin (established)<\/li><li>Procarbazine (established)<\/li><li>Raltitrexed (established)<\/li><li>Rilonacept (theoretical)<\/li><li>Rituximab (established)<\/li><li>Secukinumab (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Sirolimus (probable)<\/li><li>Streptozocin (established)<\/li><li>Tacrolimus (theoretical)<\/li><li>Teceleukin (established)<\/li><li>Tegafur (established)<\/li><li>Temsirolimus (theoretical)<\/li><li>Teniposide (established)<\/li><li>Thioguanine (established)<\/li><li>Thiotepa (established)<\/li><li>Topotecan (established)<\/li><li>Trabectedin (theoretical)<\/li><li>Treosulfan (established)<\/li><li>Trimetrexate (established)<\/li><li>Trofosfamide (established)<\/li><li>Uracil Mustard (established)<\/li><li>Ustekinumab (theoretical)<\/li><li>Vinblastine (established)<\/li><li>Vincristine (established)<\/li><li>Vincristine Sulfate Liposome (established)<\/li><li>Vindesine (established)<\/li><li>Vinorelbine (established)<\/li><\/ul>"},"2":{"id":"922388-s-4-15","title":"Moderate","mono":"<ul><li>Abatacept (probable)<\/li><li>Leflunomide (established)<\/li><li>Vaccinia Immune Globulin, Human (probable)<\/li><\/ul>"}}},"5":{"id":"922388-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Injection site reaction, Percutaneous<\/li><li><b>Gastrointestinal:<\/b>Nausea (7%)<\/li><li><b>Immunologic:<\/b>Lymphadenopathy, Axillary or cervical, induration [Percutaneous]<\/li><li><b>Renal:<\/b>Cystitis (6% to 29.5%), Dysuria (51.8% to 60%), Hematuria (26% to 39.3%), Increased frequency of urination (40% to 40.2%), Urgent desire to urinate (6% to 17.9%)<\/li><li><b>Other:<\/b>Influenza-like illness (24% to 33%), Malaise (40.2%), Shivering (9% to 33.9%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Caseous lesion, Puncture site, percutaneous<\/li><li><b>Hepatic:<\/b>Hepatitis (1% or less), Serum blood urea nitrogen raised<\/li><li><b>Immunologic:<\/b>Anaphylaxis (Rare), Infection due to Mycobacterium bovis, Intravesical and percutaneous, Suppurative lymphadenopathy, With draining sinuses, percutaneous<\/li><li><b>Musculoskeletal:<\/b>Osteomyelitis<\/li><li><b>Renal:<\/b>Nephritis, Pyelonephritis, Renal abscess, Renal failure<\/li><li><b>Reproductive:<\/b>Epididymitis, Granulomatous prostatitis, Orchitis (Less than 1%)<\/li><li><b>Respiratory:<\/b>Interstitial lung disease, Pneumonia<\/li><li><b>Other:<\/b>Disseminated mycobacteriosis, Sepsis (less than 1% to 2.7%)<\/li><\/ul>"},"6":{"id":"922388-s-6","title":"Drug Name Info","sub":{"0":{"id":"922388-s-6-17","title":"US Trade Names","mono":"<ul><li>BCG Vaccine<\/li><li>Theracys<\/li><li>Tice BCG<\/li><\/ul>"},"2":{"id":"922388-s-6-19","title":"Class","mono":"Vaccine<br\/>"},"3":{"id":"922388-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"922388-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"922388-s-7","title":"Mechanism Of Action","mono":"<ul><li>Mucosal-Local: The effect of BCG against carcinoma is not completely understood. It may be related to an inflammatory response   and possibly also to an immune response .<\/li><li>Intravesical BCG suspension produces a granulomatous response locally and in regional lymph nodes ; the inflammatory response stimulates production of macrophages that have tumoricidal effects          . The presence of interleukin-2, which is a substance produced by activated helper T lymphocytes and which activates natural killer cells, has also been noted in the urine of patients who responded to BCG treatment . However, the relationship of these effects to the antineoplastic effect of BCG is unknown .<\/li><li>Induces active immunity against tuberculosis by unknown mechanism; may involve stimulating the reticuloendothelial system (RES) to produce macrophages and other activated cells that prevent multiplication of virulent  Mycobacterium tuberculosis    .<\/li><li>Viability and immunogenicity may vary between strains   and viability varies between lots of any one strain . With intracavitary BCG, positive conversion of tuberculin (purified protein derivative [PPD]) skin test occurs in a majority of patients, usually after 3 to 12 weeks . Positive conversion of PPD skin test, when it occurs, is usually not permanent , although duration is variable and sometimes long .<\/li><li>Stimulates the reticuloendothelial system (RES) to produce activated cells, particularly macrophages, that prevent mycobacteria multiplication.. It is unclear whether BCG induces antitubercular antibodies. <\/li><li>BCG live vaccine induces antibodies that bind to  Mycobacterium leprae  and may be effective in providing protection against leprosy. <\/li><\/ul>"},"9":{"id":"922388-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/><ul><li>do not give IV, subQ, IM, or intradermally<\/li><li>vaccine is for percutaneous only<\/li><li>use proper procedures for handling and disposal; gloves, mask, gown, and aseptic technique must be used during preparation; a separate area for preparation is recommended<\/li><li>(percutaneous injection) (adults and children 1 month or older) reconstitute with 1 mL of sterile water for injection; swirl gently to mix<\/li><li>(percutaneous injection) (infants younger than 1 month) reconstitute with 2 mL of sterile water for injection; swirl gently to mix<\/li><li>(percutaneous injection) preferred site of vaccination is the deltoid region<\/li><li>(percutaneous injection) position area to maintain a horizontal surface; drop vaccine dose from syringe and needle onto horizontal skin surface and spread over a 1 by 2 inch area using the edge of the multiple puncture device, tense skin by pulling the arm firmly from underneath; apply firm downward pressure with puncture device to vaccine area, maintain pressure for 5 seconds; release from under the arm and remove the device; skin should be punctured for successful vaccination; spread vaccine over puncture site; if the skin is not punctured, repeat procedure<\/li><li>(percutaneous injection) following vaccination, loosely cover site and keep dry for 24 hours<\/li><\/ul><\/li><li><b>Intravesical<\/b><br\/><ul><li>gloves, mask, gown, and aseptic technique should be used during preparation; a separate area for preparation is recommended<\/li><li>reconstituted products should be refrigerated, protected from sunlight, and must be used within 2 hours<\/li><li>(TheraCys(R) BCG) reconstitute vial with 3 mL of preservative-free NS and gently swirl to suspend, dilute (do not filter) to a final volume of 50 mL NS; insert urethral catheter, drain bladder, and then instill suspension slowly by gravity flow; patient should be in the prone position for the first 15 minutes; have them retain the suspension as long as possible for up to 2 hours, then void while in a seated position<\/li><li>(TICE(R) BCG) reconstitute vial with 1 mL of preservative-free NS and gently swirl to suspend, dilute (do not filter) to a 49 mL NS catheter-tip syringe (final volume of 50 mL); rotate syringe gently; instill into the bladder via urinary catheter by gravity flow, patient should reposition every 15 minutes to maximize bladder exposure; retain for 2 hours<\/li><li>dispose voided urine for 6 hours following installation with an equal volume of 5% hypochlorite solution  or household bleach<\/li><li>place all unused product, packaging, and materials used for installation in biohazard container and dispose of according to local requirements<\/li><\/ul><\/li><\/ul>"},"10":{"id":"922388-s-10","title":"Monitoring","mono":"<ul><li>bladder biopsy periodically to monitor disease progression\/regression and evaluate the inflammatory response<\/li><li>signs and symptoms of toxicity after each treatment; permanently discontinue treatment for persistent fever or acute febrile illness consistent with bacillus calmette guerin infection<\/li><\/ul>"},"11":{"id":"922388-s-11","title":"How Supplied","mono":"<ul><li><b>Theracys<\/b><br\/>Intravesical Powder for Suspension: 81 MG<br\/><\/li><li><b>Tice BCG<\/b><br\/>Intravesical Powder for Suspension: 800 Million CFU<br\/><\/li><\/ul>"},"13":{"id":"922388-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause disseminated mycobacteriosis.<\/li><li>Percutaneous BCG vaccine may cause lymphadenopathy, caseous lesions, or an ulcer or purulent discharge at the injection site.<\/li><li>Intravesical BCG vaccine may cause bladder irritability, dysuria, hematuria, or increased frequency of urination.<\/li><li>Instruct patient to report signs\/symptoms of systemic BCG infection (flu-like symptoms, fever, cough, arthralgia, sweating, fatigue).<\/li><li>For intravesical administration, advise patient to not drink fluids 4 h prior to treatment.<\/li><li>Inform patient that intravesical administration is delivered through a catheter into the bladder. The patient will be asked to hold the drug in the bladder for 2 h before voiding.<\/li><li>Notify patients receiving intravesical BCG that any urine voided within 6 h after treatment should be treated as infectious waste. Patients should also sit on toilet to void, to prevent splashing.<\/li><\/ul>"}}}